Share on StockTwits

Ampio Pharmaceuticals (NASDAQ:AMPE) was downgraded by research analysts at Jefferies Group from a “buy” rating to a “hold” rating in a report released on Friday, TheFlyOnTheWall.com reports.

Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) opened at 5.66 on Friday. Ampio Pharmaceuticals has a one year low of $5.07 and a one year high of $10.86. The stock’s 50-day moving average is $6.75 and its 200-day moving average is $7.01. The company’s market cap is $294.2 million.

Ampio Pharmaceuticals (NASDAQ:AMPE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07. On average, analysts predict that Ampio Pharmaceuticals will post $-1.05 earnings per share for the current fiscal year.

A number of other firms have also recently commented on AMPE. Analysts at Aegis reiterated a “buy” rating on shares of Ampio Pharmaceuticals in a research note on Thursday.

Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

The Fly On The Wall

Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.